Prescribing information


Nurse support during patients’ first dose of MAYZENT.

About the MayzentConnect nurses

Our MayzentConnect nurse team have experience caring for a wide range of patients, including patients with MS, and have in‑depth knowledge of MAYZENT. Once MAYZENT has been prescribed, our nurse team can provide pre-initiation tests, first-dose observation and ongoing monitoring.


As a precautionary measure, patients with some pre-existing cardiac conditions* should be observed in hospital for a period of 6 hours after the first dose of MAYZENT for signs and symptoms of bradycardia.

The MayzentConnect nurse will provide close monitoring, which will include:

An electrocardiogram (ECG) – taken prior to initiation and again after 6 hours. The results are sent to IQVIA Cardiac Services (ICS). A preliminary report will be sent back to the MayzentConnect nurse within 30 minutes

Blood pressure and heart rate are monitored over 6 hours


*Patients with sinus bradycardia (heart rate <55 bpm), history of first- or second-degree (Mobitz type I) atrioventricular block, history of myocardial infarction, or history of heart failure (patients with NYHA class I and II).

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

ICS, IQVIA Cardiac Services; ECG, electrocardiogram; MS, multiple sclerosis; NYHA, New York Heart Association; SPMS, secondary progressive multiple sclerosis.


  1. MAYZENT (siponimod) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | February 2022 | 153212

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]